<DOC>
	<DOCNO>NCT01220934</DOCNO>
	<brief_summary>This observational , multicenter study assess efficacy safety Herceptin ( trastuzumab ) routine clinical practice patient HER2-positive advanced adenocarcinoma stomach gastro-esophageal junction . Data patient collect approximately 12 month .</brief_summary>
	<brief_title>An Observational Study Herceptin ( Trastuzumab ) Patients With HER2-positive Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Histologically confirm advanced adenocarcinoma stomach gastroesophageal junction ( GEJ ) locally advanced and/or metastatic disease HER2positive tumor Patients eligible treatment Herceptin accord judgment physician Unwilling unable sign inform consent form Any contraindication , interaction incompatibility Herceptin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>